Review
Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 2: β-Blockers
James M. Wright
CMAJ July 25, 2000 163 (2) 188-192;
James M. Wright
Dr. Wright is Professor, Departments of Medicine and Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC.
Article Figures & Tables
Tables
In this issue
Article tools
Respond to this article
Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 2: β-Blockers
James M. Wright
CMAJ Jul 2000, 163 (2) 188-192;
Jump to section
- Article
- Abstract
- What is a β-blocker?
- What is the evidence that β-blockers reduce cardiovascular morbidity and mortality?
- How efficacious are β-blockers in lowering blood pressure?
- Do β-blockers and other drugs differ in tolerability?
- Do β-blockers have advantages in terms of convenience or cost?
- In which patients with elevated blood pressure is a β-blocker the drug of first choice?
- Conclusion
- Footnotes
- References
- Figures & Tables
- Responses
- Metrics
Related Articles
- No related articles found.
Cited By...
- Temporal Characteristics of cAMP Response Element-Mediated Gene Transcription: Requirement for Sustained cAMP Production
- Agonist Actions of "{beta}-Blockers" Provide Evidence for Two Agonist Activation Sites or Conformations of the Human {beta}1-Adrenoceptor
- The double-edged sword of COX-2 selective NSAIDs
- The value of industry-sponsored studies of initial antihypertensive therapies
- Evidence based management of hypertension: What are the elements of good treatment for hypertension?
- First-line drugs for hypertension
- First-line drugs for hypertension
- Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 3: Angiotensin-converting-enzyme inhibitors